Cargando…

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY

BACKGROUND: There has been growing interest in the therapeutic potential of Cannabidiol (CBD) stemming from independent evidence that CBD has antipsychotic and anxiolytic properties in patients with mental health disorders. CBD has been found to be non-inferior to antipsychotic medication in a 4-wee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharyya, Sagnik, Wilson, Robin, Allen, Paul, Bossong, Matthijs, Appiah-Kusi, Elizabeth, McGuire, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888230/ http://dx.doi.org/10.1093/schbul/sby014.067

Ejemplares similares

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2020)

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels
por: Bossong, Matthijs G, et al.
Publicado: (2018)

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
por: Appiah-Kusi, E., et al.
Publicado: (2020)

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
por: Davies, Cathy, et al.
Publicado: (2021)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2019)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
por: Ranganathan, Mohini, et al.
Publicado: (2018)

The Impact of Cannabidiol on Human Brain Function: A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2021)

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2018)

The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
por: Wilson, Robin Paul, et al.
Publicado: (2018)

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
por: Colizzi, Marco, et al.
Publicado: (2019)

17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA
por: McGuire, Philip, et al.
Publicado: (2018)

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
por: Colizzi, Marco, et al.
Publicado: (2017)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

The Placebo Effect in Psychosis: Why It Matters and How to Measure It
por: Hird, Emily J., et al.
Publicado: (2023)

Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study
por: Patel, Rashmi, et al.
Publicado: (2016)

Cannabinoids, reward processing, and psychosis
por: Gunasekera, Brandon, et al.
Publicado: (2021)

Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis
por: Modinos, Gemma, et al.
Publicado: (2018)

Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial
por: Dixon, T., et al.
Publicado: (2023)

Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms
por: Modinos, Gemma, et al.
Publicado: (2017)

F102. CHANGE IN PATTERNS OF CANNABIS AND OTHER SUBSTANCE USE OVER TIME IN EARLY PSYCHOSIS- EXAMINING THE EFFECT OF DEVELOPMENT OF PSYCHOSIS
por: Sami, Musa, et al.
Publicado: (2018)

Neurophysiology for Detection of High Risk for Psychosis
por: Pantlin, Lara N., et al.
Publicado: (2016)

Neurophysiology in psychosis: The quest for disease biomarkers
por: Wang, Baihan, et al.
Publicado: (2022)

Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review
por: van der Steur, Sanne J., et al.
Publicado: (2020)

Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes
por: Modinos, Gemma, et al.
Publicado: (2021)

Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
por: Colizzi, Marco, et al.
Publicado: (2020)

173 Relationship Between Allergic Rhinitis and Dental-Facial Abnormalities
por: Medina, Miguel Alejandro
Publicado: (2012)

S17.3 PK/PD in the treatment of hospital-acquired pneumonia
Publicado: (2005)

The effect of placebo and neurophysiological involvements
por: Galli, Federica, et al.
Publicado: (2004)

Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study
por: Howes, Oliver D., et al.
Publicado: (2019)

A Comparison of Cognitive Performance in Patients With Parkinson's Disease Psychosis According to Psychosis Severity: A Meta-Analysis
por: Gosse, Luca, et al.
Publicado: (2023)

Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis
por: Bonoldi, Ilaria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5immhl24mslmjfrhamae1o4u5b